Key Details
Price
$9.39Annual ROE
-63.15%Beta
0.99Events Calendar
Next earnings date:
Jan 08, 2025Recent quarterly earnings:
Oct 03, 2024Recent annual earnings:
July 16, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market open on Wednesday, January 8, 2025, followed by a Virtual NanoKnife System investor event. Fiscal 2025 Second Quarte.
AngioDynamics' latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient outcomes.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate tissue ablation. The Company received clearance for the NanoKnife System for prostate tissue ablation follow.
ANGO enhances its offerings and expands the breadth of its products and services. However, macro challenges are likely to continue to hurt its performance.
AngioDynamics announces the receipt of CPT Category I code for IRE technology.
AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business.
ANGO shows growth potential with its NanoKnife system and expanding U.S. sales but faces challenges from pricing pressure and macroeconomic factors.
Investors didn't like the medical technology company's fiscal 2025 Q1 update.
AngioDynamics (ANGO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.12 per share a year ago.
FAQ
- What is the primary business of AngioDynamics?
- What is the ticker symbol for AngioDynamics?
- Does AngioDynamics pay dividends?
- What sector is AngioDynamics in?
- What industry is AngioDynamics in?
- What country is AngioDynamics based in?
- When did AngioDynamics go public?
- Is AngioDynamics in the S&P 500?
- Is AngioDynamics in the NASDAQ 100?
- Is AngioDynamics in the Dow Jones?
- When was AngioDynamics's last earnings report?
- When does AngioDynamics report earnings?
- Should I buy AngioDynamics stock now?